Armata Pharmaceuticals (ARMP) Accounts Payables (2013 - 2026)

Armata Pharmaceuticals has disclosed Accounts Payables across 14 years of filings, most recently posting $1.4 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.4 million, up 128.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 128.75% YoY), and the FY2025 annual result was $1.7 million, down 17.03% from the prior year.
• Accounts Payables came in at $1.4 million for Q1 2026 at Armata Pharmaceuticals, down from $1.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $9.6 million in Q2 2023 to a low of $633000.0 in Q1 2025.
• The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $3.1 million.
• Across the five-year window, Accounts Payables jumped 430.23% in 2022 and plunged 85.28% in 2024, its largest moves.
• Armata Pharmaceuticals' Accounts Payables stood at $6.0 million in 2022, then sank by 82.05% to $1.1 million in 2023, then jumped by 89.75% to $2.1 million in 2024, then dropped by 17.03% to $1.7 million in 2025, then decreased by 15.07% to $1.4 million in 2026.
• The last three Accounts Payables figures came in at $1.4 million (Q1 2026), $1.7 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.